Literature DB >> 25589622

Gain of HIF-1α under normoxia in cancer mediates immune adaptation through the AKT/ERK and VEGFA axes.

Young-Ho Lee1, Hyun Cheol Bae2, Kyung Hee Noh3, Kwon-Ho Song1, Sang-kyu Ye4, Chih-Ping Mao5, Kyung-Mi Lee6, T-C Wu7, Tae Woo Kim8.   

Abstract

PURPOSE: Adaptation to host immune surveillance is now recognized as a hallmark of cancer onset and progression, and represents an early, indispensable event in cancer evolution. This process of evolution is first instigated by an immune selection pressure imposed by natural host surveillance mechanisms and may then be propagated by vaccination or other types of immunotherapy. EXPERIMENTAL
DESIGN: We developed a system to simulate cancer evolution in a live host and to dissect the mechanisms responsible for adaptation to immune selection. Here, we show that the oxygen-sensitive α subunit of hypoxia-inducible factor 1 (HIF-1α) plays a central role in cancer immune adaptation under conditions of normal oxygen tension.
RESULTS: We found that tumor cells gain HIF-1α in the course of immune selection under normoxia and that HIF-1α renders tumor cells resistant to lysis by tumor-specific cytotoxic T lymphocytes (CTL) in culture and in mice. The effects of HIF-1α on immune adaptation were mediated through VEGFA-dependent activation of the AKT and ERK signaling pathways, which induced an antiapoptotic gene expression network in tumor cells.
CONCLUSIONS: Our study therefore establishes a link between immune selection, overexpression of HIF-1α, and cancer immune adaptation under normoxia, providing new opportunities for molecular intervention in patients with cancer. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25589622      PMCID: PMC4359944          DOI: 10.1158/1078-0432.CCR-14-1979

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  25 in total

1.  Blocking hypoxia-induced autophagy in tumors restores cytotoxic T-cell activity and promotes regression.

Authors:  Muhammad Zaeem Noman; Bassam Janji; Bozena Kaminska; Kris Van Moer; Sandrine Pierson; Piotr Przanowski; Stéphanie Buart; Guy Berchem; Pedro Romero; Fathia Mami-Chouaib; Salem Chouaib
Journal:  Cancer Res       Date:  2011-08-02       Impact factor: 12.701

2.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.

Authors:  P H Maxwell; M S Wiesener; G W Chang; S C Clifford; E C Vaux; M E Cockman; C C Wykoff; C W Pugh; E R Maher; P J Ratcliffe
Journal:  Nature       Date:  1999-05-20       Impact factor: 49.962

3.  Hypoxia-dependent inhibition of tumor cell susceptibility to CTL-mediated lysis involves NANOG induction in target cells.

Authors:  Meriem Hasmim; Muhammad Zaeem Noman; Jessica Lauriol; Houssem Benlalam; Aude Mallavialle; Filippo Rosselli; Fathia Mami-Chouaib; Catherine Alcaide-Loridan; Salem Chouaib
Journal:  J Immunol       Date:  2011-09-12       Impact factor: 5.422

Review 4.  Natural innate and adaptive immunity to cancer.

Authors:  Matthew D Vesely; Michael H Kershaw; Robert D Schreiber; Mark J Smyth
Journal:  Annu Rev Immunol       Date:  2011       Impact factor: 28.527

5.  Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1.

Authors:  J A Forsythe; B H Jiang; N V Iyer; F Agani; S W Leung; R D Koos; G L Semenza
Journal:  Mol Cell Biol       Date:  1996-09       Impact factor: 4.272

6.  Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion.

Authors:  Ken-Yu Lin; Dan Lu; Chien-Fu Hung; Shiwen Peng; Lanqing Huang; Chunfa Jie; Francisco Murillo; Jesse Rowley; Ya-Chea Tsai; Liangmei He; Dae-Jin Kim; Elizabeth Jaffee; Drew Pardoll; T-C Wu
Journal:  Cancer Res       Date:  2007-02-15       Impact factor: 12.701

7.  Expression of hypoxia-related tissue factors correlates with diminished survival of adjuvantly treated patients with chromosome 1p aberrant oligodendroglial neoplasms and therapeutic implications.

Authors:  Peter Birner; Matthias Preusser; Ellen Gelpi; Johannes Berger; Brigitte Gatterbauer; Inge M Ambros; Peter F Ambros; Till Acker; Karl H Plate; Adrian L Harris; Johannes A Hainfellner
Journal:  Clin Cancer Res       Date:  2004-10-01       Impact factor: 12.531

8.  The cooperative induction of hypoxia-inducible factor-1 alpha and STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis.

Authors:  Muhammad Zaeem Noman; Stéphanie Buart; Jos Van Pelt; Catherine Richon; Meriem Hasmim; Nathalie Leleu; Wictoria Maria Suchorska; Abdelali Jalil; Yann Lecluse; Faten El Hage; Massimo Giuliani; Christophe Pichon; Bruno Azzarone; Nathalie Mazure; Pedro Romero; Fathia Mami-Chouaib; Salem Chouaib
Journal:  J Immunol       Date:  2009-03-15       Impact factor: 5.422

9.  Activation of Akt as a mechanism for tumor immune evasion.

Authors:  Kyung Hee Noh; Tae Heung Kang; Jin Hee Kim; Sara I Pai; Ken Y Lin; Chien-Fu Hung; T-C Wu; Tae Woo Kim
Journal:  Mol Ther       Date:  2008-12-23       Impact factor: 11.454

Review 10.  Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.

Authors:  Robert D Schreiber; Lloyd J Old; Mark J Smyth
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

View more
  23 in total

1.  HDAC1 Upregulation by NANOG Promotes Multidrug Resistance and a Stem-like Phenotype in Immune Edited Tumor Cells.

Authors:  Kwon-Ho Song; Chel Hun Choi; Hyo-Jung Lee; Se Jin Oh; Seon Rang Woo; Soon-Oh Hong; Kyung Hee Noh; Hanbyoul Cho; Eun Joo Chung; Jae-Hoon Kim; Joon-Yong Chung; Stephen M Hewitt; Seungki Baek; Kyung-Mi Lee; Cassian Yee; Minjoo Son; Chih-Ping Mao; T C Wu; Tae Woo Kim
Journal:  Cancer Res       Date:  2017-07-17       Impact factor: 12.701

2.  Targeting Cyclin D-CDK4/6 Sensitizes Immune-Refractory Cancer by Blocking the SCP3-NANOG Axis.

Authors:  Se Jin Oh; Hanbyoul Cho; Suyeon Kim; Suhyun Kim; Kyung Hee Noh; Kwon-Ho Song; Hyo-Jung Lee; Seon Rang Woo; Chel Hun Choi; Joon-Yong Chung; Stephen M Hewitt; Jae-Hoon Kim; Seungki Baek; Kyung-Mi Lee; Cassian Yee; Hae-Chul Park; Tae Woo Kim
Journal:  Cancer Res       Date:  2018-02-06       Impact factor: 12.701

3.  Mitochondrial reprogramming via ATP5H loss promotes multimodal cancer therapy resistance.

Authors:  Kwon-Ho Song; Jae-Hoon Kim; Young-Ho Lee; Hyun Cheol Bae; Hyo-Jung Lee; Seon Rang Woo; Se Jin Oh; Kyung-Mi Lee; Cassian Yee; Bo Wook Kim; Hanbyoul Cho; Eun Joo Chung; Joon-Yong Chung; Stephen M Hewitt; Tae-Wook Chung; Ki-Tae Ha; Young-Ki Bae; Chih-Ping Mao; Andrew Yang; T C Wu; Tae Woo Kim
Journal:  J Clin Invest       Date:  2018-08-20       Impact factor: 14.808

Review 4.  The role of hypoxic signalling in metastasis: towards translating knowledge of basic biology into novel anti-tumour strategies.

Authors:  Joaquín Araos; Jonathan P Sleeman; Boyan K Garvalov
Journal:  Clin Exp Metastasis       Date:  2018-08-31       Impact factor: 5.150

Review 5.  Hypoxia: Signaling the Metastatic Cascade.

Authors:  Erinn B Rankin; Jin-Min Nam; Amato J Giaccia
Journal:  Trends Cancer       Date:  2016-06-02

6.  iASPP is essential for HIF-1α stabilization to promote angiogenesis and glycolysis via attenuating VHL-mediated protein degradation.

Authors:  Dong Zhao; Shanliang Zheng; Xingwen Wang; Hao Liu; Kunming Zhao; Li Li; Ying Hu
Journal:  Oncogene       Date:  2022-02-15       Impact factor: 8.756

Review 7.  Hypoxic control of metastasis.

Authors:  Erinn B Rankin; Amato J Giaccia
Journal:  Science       Date:  2016-04-07       Impact factor: 47.728

8.  Jolkinolide A and Jolkinolide B Inhibit Proliferation of A549 Cells and Activity of Human Umbilical Vein Endothelial Cells.

Authors:  Lei Shen; Shan-Qiang Zhang; Lei Liu; Yu Sun; Yu-Xuan Wu; Li-Ping Xie; Ji-Cheng Liu
Journal:  Med Sci Monit       Date:  2017-01-14

Review 9.  The multifaceted role of autophagy in tumor evasion from immune surveillance.

Authors:  Bassam Janji; Elodie Viry; Etienne Moussay; Jérôme Paggetti; Tsolère Arakelian; Takouhie Mgrditchian; Yosra Messai; Muhammad Zaeem Noman; Kris Van Moer; Meriem Hasmim; Fathia Mami-Chouaib; Guy Berchem; Salem Chouaib
Journal:  Oncotarget       Date:  2016-04-05

10.  LC3B upregulation by NANOG promotes immune resistance and stem-like property through hyperactivation of EGFR signaling in immune-refractory tumor cells.

Authors:  Suyeon Kim; Hanbyoul Cho; Soon-Oh Hong; Se Jin Oh; Hyo-Jung Lee; Eunho Cho; Seon Rang Woo; Joon Seon Song; Joon-Yong Chung; Sung Wook Son; Sang Min Yoon; Yu-Min Jeon; Seunghyun Jeon; Cassian Yee; Kyung-Mi Lee; Stephen M Hewitt; Jae-Hoon Kim; Kwon-Ho Song; Tae Woo Kim
Journal:  Autophagy       Date:  2020-08-14       Impact factor: 16.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.